CD274 and urinary tract infection: Cancer patients suffering from renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC) treated with antiprogrammed cell death ligand-1 (PD-L1) or PD-L1 plus CTLA-4 mAb monotherapy who were also undergoing treatment with antibiotics (β-lactam or quinolones for pneumonia or urinary tract infections) in the beginning were examined for thirty days for gut microbiota diversity and composition leading to dysbiosis.